Medicare Drug Price Negotiation: ‘Spillover Effect’ on Private Market Remains Fuzzy

The Biden administration on Aug. 29 released its long-awaited list of the first 10 drugs that will be subject to price negotiation in the Medicare program, representing the first major step toward implementing the most ambitious drug-pricing reform in the Inflation Reduction Act (IRA).

While the new price-negotiation program will apply only to Medicare — not employer-based or individual market plans — industry experts say it will almost certainly affect the commercial insurance market indirectly. But they tell AIS Health, a division of MMIT, that exactly what the impact will look like hasn’t fully come into focus.

0 Comments
© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

drugs-drug-bottle-and-bills
September 1

Majority of Drugs Selected for Price Negotiation Are on ‘Preferred’ Tiers in Medicare

READ MORE
white-house
August 18

For Some Insurers, Inflation Reduction Act’s Anniversary Is Reason to Celebrate

READ MORE
congress
August 18

Part D Changes in Inflation Reduction Act Could Lead to Tighter Formulary Management

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today